Medxy AI – Page 132

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

By MedXY 10/15/2025

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.

Diabetes & Endocrinology news Oncology

Enhancing Prognostication in Papillary Thyroid Cancer: Integrating BRAF and TERT Mutations into the AJCC Staging System

By MedXY 10/15/2025

Incorporating BRAF and TERT promoter mutations into the AJCC classification for papillary thyroid cancer significantly improves mortality risk prediction, refining patient stratification beyond traditional clinical staging.

news Oncology Pediatrics

Smoothing the Leap to Adult Care: EU‑CAYAS‑NET Recommendations for Transition of Childhood and Adolescent Cancer Survivors

By MedXY 10/15/2025

EU‑CAYAS‑NET issues 44 strong, evidence‑based recommendations to standardize and improve transitions from paediatric to adult survivorship care for those diagnosed with cancer at 0–21 years, emphasizing planned transfer, risk‑based follow‑up, care coordination, and patient‑centred supports.

Diabetes & Endocrinology Ophthalmology Specialties

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

By MedXY 10/15/2025

The RESTORE-1 phase 3 trial demonstrates that IBI311 significantly improves proptosis and inflammation in Chinese patients with active thyroid eye disease, with a favorable safety profile.

Oncology Pathology & Lab Medicine Specialties

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

By MedXY 10/15/2025

International experts issue consensus guidelines for sampling and reporting pathological response to neoadjuvant therapy in renal cell carcinoma, recommending standardized specimen sampling and quantification of residual viable tumor to enable reliable trial endpoints and future clinical use.

news Oncology

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

By MedXY 10/15/2025

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

news

全ゲノム配列解析と死亡データを連携して乳がんの予後と治療の洞察を解明

By MedXY 10/15/2025

この英国の後ろ向き研究では、全ゲノム配列解析を臨床情報と死亡データと統合することで、特にER陽性HER2陰性サブタイプの乳がんにおける予後予測と治療標的の同定が向上することが示されました。

news Oncology Respiratory

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

By MedXY 10/15/2025

The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeutic option with manageable safety.

news Oncology Respiratory

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY 10/15/2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety profile, suggesting a viable alternative treatment approach.

General Surgery news

Optimizing Mesh Weight to Reduce Recurrence Reoperations in Laparoscopic Inguinal Hernia Repair

By MedXY 10/15/2025

A Danish cohort study identifies that using mesh weighing 45-65 g/m² in laparoscopic inguinal hernia repair results in the lowest reoperation rate for recurrence, guiding surgical mesh selection for better patient outcomes.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Family Medicine & Nutrition news Psychiatry

Comparative Effectiveness of PTSD Treatments in Primary Care: Insights from a Pragmatic Randomized Trial

By MedXY 10/15/2025

A pragmatic trial comparing SSRIs and written exposure therapy in primary care PTSD treatment found similar effectiveness initially; switching to SNRI was superior to WET augmentation for SSRI nonresponders.

news Psychiatry Public Health

Rising Trends in Stimulant Use Disorder Diagnoses Among Adolescent and Young Adult Medicaid Enrollees: Implications for Clinical Practice

By MedXY 10/15/2025

Stimulant use disorder diagnoses in young adult Medicaid enrollees have markedly increased from 2001 to 2020, especially for noncocaine psychostimulants, highlighting an urgent need for targeted interventions and evidence-based treatments amid rising overdose risks.

Dermatology Nephrology news

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

By MedXY 10/15/2025

A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.

Hematology-Oncology news

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

By MedXY 10/14/2025

The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Cardiology news

Dual Versus Single Antiplatelet Therapy After Valve-in-Valve TAVI: Balancing Stroke Prevention and Bleeding Risk

By MedXY 10/14/2025

This study compares dual and single antiplatelet therapy after valve-in-valve transcatheter aortic valve implantation, finding dual therapy reduces stroke risk without increasing bleeding or valve deterioration at one year.

Cardiology Specialties

CDKL1 Variants and Their Role in Thoracic Aortic Aneurysm and Dissection: Illuminating Cilia-Linked Pathogenesis

By MedXY 10/14/2025

This study identifies CDKL1 gene variants impairing ciliary function as novel genetic contributors to thoracic aortic aneurysm and dissection, highlighting an emerging pathogenic link between cilia biology and vascular disease.

Hematology-Oncology news Oncology

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

By MedXY 10/14/2025

Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a promising therapeutic strategy.

Hematology-Oncology news Rheumatology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

By MedXY 10/14/2025

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

Enhancing Prognostication in Papillary Thyroid Cancer: Integrating BRAF and TERT Mutations into the AJCC Staging System

Smoothing the Leap to Adult Care: EU‑CAYAS‑NET Recommendations for Transition of Childhood and Adolescent Cancer Survivors

IBI311, an IGF-1R Inhibitor, Shows Promising Results for Active Thyroid Eye Disease in Chinese Patients: Insights from the RESTORE-1 Trial

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

全ゲノム配列解析と死亡データを連携して乳がんの予後と治療の洞察を解明

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

Optimizing Mesh Weight to Reduce Recurrence Reoperations in Laparoscopic Inguinal Hernia Repair

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

Comparative Effectiveness of PTSD Treatments in Primary Care: Insights from a Pragmatic Randomized Trial

Rising Trends in Stimulant Use Disorder Diagnoses Among Adolescent and Young Adult Medicaid Enrollees: Implications for Clinical Practice

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

Dual Versus Single Antiplatelet Therapy After Valve-in-Valve TAVI: Balancing Stroke Prevention and Bleeding Risk

CDKL1 Variants and Their Role in Thoracic Aortic Aneurysm and Dissection: Illuminating Cilia-Linked Pathogenesis

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

Precision Medicine in Gestational Diabetes: Decoding Heterogeneity Through Data-Driven Phenotypic Clustering and Risk Stratification

Decoding the Diabetic Heart: Five Unique Proteomic Markers Unveil Heart Failure Risk in Patients with Diabetes

Sex-Specific Risk Thresholds in Aortic Regurgitation: Challenging the One-Size-Fits-All Approach to LV Remodeling

Evolution and Future Frontiers of PCSK9 Inhibition: From Genetic Discovery to Genomic Medicine